Long-term Follow-up Study of BHC001 for TDT

Recruiting now

Conditions studied: Thalassemia, Beta

In brief

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

Key facts

Study ID

NCT06314529

Run by

Bioray Laboratories

People needed

6

Starts

2022-12-14

Expected to finish

2037-05-10

Last updated by the study team

2024-03-18

Who can join

Age: 5 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

You may not qualify if…

• There are no exclusion criteria for this study

Where it is running

• The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army — Nanning, Guangxi, China (enrolling)
• Xiangya Hospital of Central South University — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.